Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TRAVERE THERAPEUTICS, INC.

(TVTX)
  Report
Delayed Nasdaq  -  04:00 2022-12-07 pm EST
20.21 USD   +0.55%
12/05Wells Fargo Starts Travere Therapeutics at Overweight With $28 Price Target
MT
11/17Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
AQ
11/16TravereáTherapeutics ReportsáInducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2022 12/02/2022 12/05/2022 12/06/2022 12/07/2022 Date
19.54(c) 20.08(c) 20.01(c) 20.1(c) 20.21(c) Last
586 032 994 071 647 122 514 002 546 570 Volume
-2.93% +2.76% -0.35% +0.45% +0.55% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 212 M - -
Net income 2022 -274 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,73x
Yield 2022 -
Sales 2023 277 M - -
Net income 2023 -217 M - -
Net cash position 2023 183  - -
P/E ratio 2023 -6,72x
Yield 2023 -
Capitalization 1 297 M 1 297 M -
Capi. / Sales 2022 6,12x
EV / Sales 2023 4,69x
Nbr of Employees 310
Free-Float 98,7%
More Financials
Company
Travere Therapeutics, Inc. is a biopharmaceutical company. It is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom... 
Sector
Biotechnology & Medical Research
Calendar
12/07 | 12:15pmPresentation
More about the company
Ratings of Travere Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about TRAVERE THERAPEUTICS, INC.
12/05Wells Fargo Starts Travere Therapeutics at Overweight With $28 Price Target
MT
11/17Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
AQ
11/16TravereáTherapeutics ReportsáInducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
11/16TravereáTherapeutics ReportsáInducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/15Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International..
GL
11/15Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International..
AQ
11/09Travere Therapeutics to Present at Upcoming Investor Conferences
GL
11/09Travere Therapeutics to Present at Upcoming Investor Conferences
AQ
10/28Travere Therapeutics Q3 Non-GAAP Loss Widens as Revenue Falls
MT
10/27TRAVERE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
10/27Travere Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
10/27Transcript : Travere Therapeutics, Inc., Q3 2022 Earnings Call, Oct 27, 2022
CI
10/27Travere : Q3 Earnings Snapshot
AQ
10/27Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q3 Revenue $53.5M, vs. Street Est of..
MT
10/27Travere Therapeutics Reports Third Quarter 2022 Financial Results
GL
More news
News in other languages on TRAVERE THERAPEUTICS, INC.
10/28La perte non GAAP du troisième trimestre de Travere Therapeutics s'accentue en raison d..
10/27Travere Therapeutics, Inc. annonce ses résultats pour le troisième trimestre et les neu..
10/14Mise à jour sectorielle : Les actions du secteur de la santé son..
10/13Travere voit sa demande d'homologation du Sparsentan prolongée alors que la FDA demande..
10/13Travere Therapeutics fait le point sur la réglementation de son programme Sparsentan po..
More news
Analyst Recommendations on TRAVERE THERAPEUTICS, INC.
More recommendations
ETFs positioned on TRAVERE THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Invesco Dynamic Pharmaceuticals ETF - USD3.2%1.09%United_States
Direxion Fallen Knives ETF - USD1.92%-9.78%-NC
Virtus LifeSci Biotech Products ETF - USD1.58%-0.80%United_States
ALPS Medical Breakthroughs ETF - USD0.96%-4.81%United_States
SPDR S&P Biotech ETF - USD0.81%0.76%United_States
More ETFs positioned on TRAVERE THERAPEUTICS, INC.
Chart TRAVERE THERAPEUTICS, INC.
Duration : Period :
Travere Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRAVERE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 20,21 $
Average target price 32,20 $
Spread / Average Target 59,3%
EPS Revisions
Managers and Directors
Eric M. Dube President, Chief Executive Officer & Director
Chris Cline Chief Financial Officer
Gary A. Lyons Chairman
William E. Rote Senior VP, Head-Research & Development
Jula Inrig Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TRAVERE THERAPEUTICS, INC.-35.24%1 297
REGENERON PHARMACEUTICALS, INC.18.36%81 626
VERTEX PHARMACEUTICALS41.99%81 520
BIONTECH SE-36.92%39 522
WUXI APPTEC CO., LTD.-33.48%32 802
GENMAB A/S23.27%29 855